Observational Study of Lumigan® 0.01% Treatment for Patients With Primary Open Angle Glaucoma or Ocular Hypertension

Allergan

Status: Completed

Conditions: Ocular Hypertension; Glaucoma, Open-Angle

Treatments: Drug: bimatoprost 0.01% ophthalmic solution

Study type: Observational

Funder types: Industry

Identifiers

NCT01489670

MAF/AGN/OPH/GLA/032

Details and patient eligibility

About

This study will assess the efficacy, safety, tolerability and persistence of use of Lumigan ® 0.01% in patients diagnosed with primary open-angle glaucoma or ocular hypertension who are treated per routine clinical practice.

Enrollment: 387 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of primary open-angle glaucoma or ocular hypertension
• Lumigan® 0.01% prescribed either as monotherapy or adjunctive to beta-blocker therapy

Exclusion criteria

• None

Trial design

387 participants in 1 patient group

Lumigan® 0.01%

Description:

Patients with primary open-angle glaucoma or ocular hypertension treated with Lumigan® 0.01% in clinical practice.

Treatment:

Drug: bimatoprost 0.01% ophthalmic solution